Coherent Identifier About this item: 20.500.12592/6qp98b

SOGC Statement on COVID-19 Vaccination in Pregnancy

26 May 2021

Summary

US data reporting on nearly 4,000 pregnant women who received either the Pfizer-BioNtech vaccine or the Moderna vaccine reported no differences in the rates of adverse pregnancy and neonatal outcomes for those women who were pregnant and compared to pre-pandemic rates.11 The Developmental and Reproductive Toxicity (DART) animal studies for the Moderna and Pfizer-BioNTech vaccines are ongoing. [...] NACI has advised “that a complete vaccine series with a COVID-19 vaccine may be offered to pregnant individuals in the authorized age group, without contraindications to the vaccine, if a risk assessment deems that the benefits outweigh the potential risks for the individual and the fetus, and if informed consent includes discussion about the absence of evidence on the use of COVID-19 vaccine in t. [...] Vaccination of the pregnant patient in the context of limited vaccine supply Certain jurisdictions may manage interruptions of the vaccine supply chain by delaying administration of the second dose of a COVID-19 vaccine. [...] Vaccine effectiveness following a single dose of the mRNA and non-replicating viral vector vaccines has been thoroughly reviewed at a federal level to inform jurisdictional decisions to delay administration of second doses of a COVID-19.7 There are no physiologic reasons to anticipate that the effect of delaying the second dose of the COVID-19 vaccine would be different for a pregnant individual c. [...] The decision of whether to complete the vaccine series during pregnancy should be based on an assessment of the potential risks of not being completely vaccinated during pregnancy, compared to the potential risks of receiving the vaccine during pregnancy (as discussed above).

Tags

academic council

Pages
10
AOM
Association of Ontario Midwives

Create your FREE account to get started